Clinical effect of MaiLuoShuTong pills combined with dalteparin on parathyroid function recovery after total thyroidectomy

Abstract

The present study aims to investigate the therapeutic efficacy and safety of the combined use of MaiLuoShuTong pills and dalteparin in managing post-operative hypoparathyroidism following total thyroidectomy. Data from 928 thyroid cancer patients who underwent total thyroidectomy and lymph node dissection at the Department of Breast and Thyroid Surgery, Zibo Central Hospital, between May 2021 and October 2022, were retrospectively analyzed. Among these patients, 261 experienced post-operative decreased parathyroid function. Of these, 151 patients (anticoagulant group) received MaiLuoShuTong pills combined with dalteparin anticoagulant therapy and calcium supplementation starting on post-operative day 1. The remaining 110 patients (control group) received only post-operative calcium supplementation. The incidence of permanent hypoparathyroidism, the average time to normalization of parathyroid function, and the average post-operative days until Hemovac removal and total drainage volume were recorded. Treatment efficacy, as well as serum parathyroid hormone (PTH) and calcium levels were compared between the two groups. The anticoagulant group had a 0% incidence of permanent hypoparathyroidism, which was significantly lower than the 3.64% incidence in the control group (P < 0.05). There were no significant differences in the number of post-operative days until Hemovac removal (P = 0.28) or total drainage volume (P = 0.59) between the two groups. Parathyroid function in the anticoagulant group recovered significantly faster at 15, 30, 90, and 180 days compared to the control group (P < 0.05). Post-operative hypoparathyroidism is a common complication after total thyroidectomy. The combined use of MaiLuoShuTong pills and dalteparin anticoagulant therapy can promote parathyroid function recovery, improve PTH and serum calcium levels, enhance clinical efficacy, reduce the incidence of permanent functional impairment, and ensure a safe and reliable post-operative treatment outcome.

Keywords

Thyroid malignancy / Total thyroid resection / Hypoparathyroid function / Anticoagulation therapy / Infarction of the parathyroid gland

Funding

This work was supported by the Zibo Medical and Health Research Project (Grant number: 20230401040).

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Haymart MR. Progress and challenges in thyroid cancer management. Endocr Pract. 2021; 27(12):1260-1263. doi: 10.1016/j.eprac.2021.09.006

[2] Reiners C, Drozd V. Radiation as risk factor, early diagnosis, therapy, and follow-up of differentiated thyroid cancer. Front Endocrinol (Lausanne). 2021; 12:797969. doi: 10.3389/fendo.2021.797969

[3] Broekhuis JM, Li C, Chen HW, et al. Patient-reported financial burden in thyroid cancer. J Surg Res. 2021; 266:160-167. doi: 10.1016/j.jss.2021.03.051

[4] Zhu J, Tian W, Xu Z, et al. Expert consensus statement on parathyroid protection in thyroidectomy. Ann Transl Med. 2015; 3(16):230. doi: 10.3978/j.issn.2305-5839.2015.08.20

[5] Yao XY, Zhou Y, Chen SJ, et al. Is there a regular pattern in the recovery of parathyroid function after thyroid cancer surgery? Cancer Manag Res. 2021; 13:6891-6899. doi: 10.2147/CMAR.S326705

[6] Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: Etiologies and clinical features. J Clin Endocrinol Metab. 2016; 101(6):2300-2312. doi: 10.1210/jc.2015-3909

[7] Salem FA, Bergenfelz A, Nordenström E, Almquist M. Central lymph node dissection and permanent hypoparathyroidism after total thyroidectomy for papillary thyroid cancer: Population‐based study. Br J Surg. 2021; 108(6):684-690. doi: 10.1002/bjs.12028

[8] Orloff LA, Wiseman SM, Bernet VJ, et al. American thyroid association statement on postoperative hypoparathyroidism: Diagnosis, prevention, and management in adults. Thyroid. 2018; 28(7):830-841. doi: 10.1089/thy.2017.0309

[9] Annebäck M, Hedberg J, Almquist M, Stålberg P, Norlén O. Risk of permanent hypoparathyroidism after total thyroidectomy for benign disease: A nationwide population-based cohort study from Sweden. Ann Surg. 2021; 274(6):e1202-e1208. doi: 10.1097/SLA.0000000000003800

[10] Colombo C, De Leo S, Di Stefano M, et al. Total thyroidectomy versus lobectomy for thyroid cancer: Single-center data and literature review. Ann Surg Oncol. 2021; 28(8):4334-4344. doi: 10.1245/s10434-020-09481-8

[11] Parameswaran R, Samuel M, Satish RL, et al. Parathyroid allotransplantation to treat post-thyroidectomy hypoparathyroidism: A review of case studies. Surgeon. 2021; 19(3):183-192. doi: 10.1016/j.surge.2020.06.008

[12] Díez JJ, Anda E, Sastre J, et al. Recovery of parathyroid function in patients with thyroid cancer treated by total thyroidectomy: An analysis of 685 patients with hypoparathyroidism at discharge of surgery. Endocrinol Diabetes Nutr (Engl Ed). 2021; 68(6):398-407. doi: 10.1016/j.endien.2021.10.009

[13] Koimtzis GD, Stefanopoulos L, Giannoulis K, Papavramidis TS. What are the real rates of temporary hypoparathyroidism following thyroidectomy? It is a matter of definition: A systematic review. Endocrine. 2021; 73(1):1-7. doi: 10.1007/s12020-021-02663-8

[14] Lončar I, Noltes ME, Dickhoff C, et al. Persistent postthyroidectomy hypoparathyroidism in the Netherlands. JAMA Otolaryngol Head Neck Surg. 2021; 147(11):959-965. doi: 10.1001/jamaoto.2021.2475

[15] Jørgensen CU, Homøe P, Dahl M, Hitz MF. Postoperative chronic hypoparathyroidism and quality of life after total thyroidectomy. JBMR Plus. 2021; 5(4):e10479. doi: 10.1002/jbm4.10479

[16] Paek SH, Lee YM, Min SY, Kim SW, Chung KW, Youn YK. Risk factors of hypoparathyroidism following total thyroidectomy for thyroid cancer. World J Surg. 2013; 37(1):94-101. doi: 10.1007/s00268-012-1809-4

[17] Moriyama T, Yamashita H, Noguchi S, et al. Intraoperative parathyroid hormone assay in patients with Graves’ disease for prediction of postoperative tetany. World J Surg. 2005; 29(10):1282-1287. doi: 10.1007/s00268-005-7880-3

[18] Erbil Y, Ozbey NC, Sari S, et al. Determinants of postoperative hypocalcemia in vitamin D-deficient Graves’ patients after total thyroidectomy. Am J Surg. 2011; 201(5):685-691. doi: 10.1016/j.amjsurg.2010.04.030

[19] Park YM, Kim JR, Oh KH, et al. Comparison of functional outcomes after total thyroidectomy and completion thyroidectomy: Hypoparathyroidism and postoperative complications. Auris Nasus Larynx. 2019; 46(1):101-105. doi: 10.1016/j.anl.2018.03.009

[20] Perigli G, Cianchi F, Giudici F, et al. Thyroidectomy for cancer: The surgeon and the parathyroid glands sparing. J Clin Med. 2021; 10(19):4323. doi: 10.3390/jcm10194323

[21] García-García E, Gómez-Gila AL, Romero-Lluch AR, et al. Hypoparathyroidism after thyroidectomy: A 20-year experience at a children’s hospital. Endocrinol Diabetes Nutr (Engl Ed). 2022; 69(2):92-97. doi: 10.1016/j.endien.2022.02.001

[22] Lim ST, Jeon YW, Gwak H, Suh YJ. Incidence, risk factors, and clinical implications of delayed hypoparathyroidism on postoperative day two following total thyroidectomy for papillary thyroid carcinoma. Endocr Pract. 2020; 26(7):768-776. doi: 10.4158/EP-2019-0544

[23] Chinese Society of Cardiovascular Diseases, Cardiovascular and Cerebrovascular Diseases Committee of the Chinese Society of Gerontology. Chinese experts consensus on warfarin anticoagulation therapy. Chin J Intern Med. 2013; 52(1):76-82. doi: 10.3760/cma.j.issn.0578-1426.2013.01.027

[24] Professional Committee of Endocrinology and Metabolic Disease, Chinese Physicians Association of Integrative Medicine, China. Guideline for diagnosis and treatment of diabetic foot with integrated traditional Chinese and Western medicine. J Tradit Chin Med. 2021; 62(12):1099-1104. doi: 10.13288/j.11-2166/r.2021.12.017